Highlights

  • Noxopharm reported new preclinical data for its cutaneous lupus candidate SOF-SKN, supporting its progression toward human trials.
  • The active component SOF-16 demonstrated a skin half-life of approximately 3.5 days, indicating potential for less frequent dosing.
  • Study results confirmed that SOF-16 remains localised within skin layers, with systemic absorption below quantifiable levels.
  • Findings support sustained suppression of inflammation while minimising risks linked to systemic immunosuppression.
  • The company has initiated engagement with a Contract Research Organisation (CRO) to prepare for the next phase of clinical development.

Noxopharm Limited (ASX:NOX) shares concluded the trading session on 22 April 2026 at AUD 0.066, remaining flat for the day. While the stock touched an intraday high of AUD 0.070, but the selling pressure emerged and pushed the stock downward pressure. NOX also remains down 26.67% over the past twelve months, reflecting sustained investor cautiousness over the long term.

Despite the market’s muted reaction, the company today released significant positive preclinical data regarding its cutaneous lupus drug candidate, SOF-SKN, which provides a clearer roadmap for upcoming human trials and highlights the drug’s potential for long-lasting, localized efficacy.

Company Overview

Noxopharm is an Australian-based biotech firm specializing in the development of treatments for cancer and inflammation, as well as technologies aimed at enhancing the safety profiles of mRNA medicines. The company’s pipeline is underpinned by two proprietary technology platforms: Sofra and Chroma.

The Sofra platform, which drives the development of SOF-SKN, is based on short nucleic acid sequences known as oligonucleotides. These molecules act on specific immune sensors to regulate inflammation at its source. While SOF-SKN is currently targeting cutaneous lupus erythematosus (CLE)—a market valued at over US$3.3 billion—the Sofra technology has broader applications. It is being evaluated for potential use in other autoimmune-related conditions, including psoriasis, dermatomyositis, rheumatoid arthritis, and diabetes.

The global autoimmune disease therapeutics market continues to grow, valued at US$163.2 billion in 2024 with projections to reach US$219.6 billion by 2035. By positioning itself within this massive industry, Noxopharm aims to leverage its novel technology to capture significant market share as it advances its clinical pipeline.

Sustained Efficacy: The Key to Future Trials

The latest data release follows the successful conclusion of the Phase 1 HERACLES clinical trial, which focused on the safety profile of SOF-SKN. With safety parameters established, the Noxopharm research team shifted its focus toward optimizing the dosing regimen—determining how frequently patients would need to apply the treatment.

In a pivotal pharmacokinetic study using an in vivo animal model, the company examined the uptake of SOF-16, the active ingredient in SOF-SKN, at the highest dose previously utilized in the HERACLES trial. The study yielded two critical insights that strengthen the drug’s value proposition:

  1. Prolonged Skin Retention: Researchers found that the half-life of SOF-16 in both normal and disease-like skin was approximately 3.5 days. This long half-life suggests that the drug remains active in the target tissue for an extended period, potentially allowing for less frequent dosing than the standard once-daily requirement. This enhancement offers significant convenience for patients and is expected to drive better adherence to treatment schedules in chronic care settings.
  2. Targeted Delivery with Minimal Systemic Exposure: A primary goal for SOF-SKN is to treat skin inflammation without affecting the rest of the body. The study confirmed that the drug remains almost entirely within the epidermis and dermis layers. Remarkably, absorption from the skin into the bloodstream was below quantifiable levels at all time points. This localized approach allows for sustained suppression of innate immune activation within the skin while avoiding the undesirable side effects associated with systemic immunosuppression.

Strategic Roadmap: Engaging the CRO

Building on these positive findings, Noxopharm has confirmed it is now in the process of engaging a Contract Research Organisation (CRO). This move is a critical step in the company’s operational timeline, as the CRO will provide the necessary infrastructure and expertise to finalize preparations for the next stage of human clinical trials and assist with the submission packages required by regulatory authorities.

CEO Dr. Olivier Laczka expressed confidence in the findings, noting that the data confirms the drug is reaching its intended targets even within the compromised environment of diseased skin. Noxopharm remains committed to providing a therapeutic solution for millions suffering from chronic inflammatory skin conditions.